A real-world perspective on the prevalence and treatment of heart failure with a reduced ejection fraction but no specific or only mild symptoms
Authors:
- Farzin BeyguiFBFarzin Beygui
- Manuel AnguitaMAManuel Anguita
- Ulrich TebbeUTUlrich Tebbe
- Josep Comin-ColetJCJosep Comin-Colet
- Michel GalinierMGMichel Galinier
- Peter BramlagePBPeter Bramlage
- Eva TurgonyiETEva Turgonyi
- Katharina LinsKLKatharina Lins
- Lynda ImekrazLILynda Imekraz
- Trinidad de FrutosTFTrinidad de Frutos
- Michael BöhmMBMichael Böhm
- 4 July 2015
- journal article
- review article
- Published by Springer Nature in Heart Failure Reviews
- Vol. 20 (5) , 545-552
Abstract
Heart failure (HF) is commonly described according to the severity of symptoms, using the New York Heart Association (NYHA) classification, and the assessment of ventricular function, by measuring the left ventricular ejection fraction (LVEF). It is important to acknowledge, however, that the severity of symptoms does not systematically correlate with the level of ventricular systolic dysfunction. Patients with no or only mild symptoms are still at high risk of HF-related morbidity and mortality. The objective of this review was to summarize the prevalence, characteristics, and treatment of patients with chronic HF and mild or no symptoms and to review epidemiological data from three recent registries conducted in Europe. From a clinical practice perspective, patients with a reduced ejection fraction who have only mild symptoms appear to represent a group of patients for whom the provision of adequate medical care is yet to be optimized. While prescription of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and beta-blockers appears to be consistently high, the use of mineralocorticoid receptor antagonists is more variable and does not appear to be in accordance with the latest clinical guidelines. As approximately half of patients with HF and a reduced LVEF have NYHA class II symptoms, significant reductions in morbidity and mortality could be achieved by more comprehensive treatment of this population.Keywords
This publication has 39 references indexed in Scilit:
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESCEuropean Heart Journal, 2012
- Eplerenone in Patients with Systolic Heart Failure and Mild SymptomsNew England Journal of Medicine, 2011
- Cardiac-Resynchronization Therapy for Mild-to-Moderate Heart FailureNew England Journal of Medicine, 2010
- Prediction of Long‐Term Survival in Chronic Heart Failure by Multiple Biomarker Assessment: A 15‐Year Prospective Follow‐Up StudyClinical Cardiology, 2010
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)European Heart Journal, 2008
- Clinical epidemiology of heart failureHeart, 2007
- Metoprolol Reverses Left Ventricular Remodeling in Patients With Asymptomatic Systolic DysfunctionCirculation, 2007
- A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart FailureNew England Journal of Medicine, 2001
- Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban populationThe Lancet, 1997
- The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart FailureNew England Journal of Medicine, 1996